You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,083,903


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,083,903
Title: Boronic ester and acid compounds, synthesis and uses
Abstract:Disclosed herein are boronic ester and acid compounds, their synthesis and uses. More specifically, disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds.
Inventor(s): Adams; Julian (Brookline, MA), Ma; Yu-Ting (Cambridge, MA), Stein; Ross (Sudbury, MA), Baevsky; Matthew (Cambridge, MA), Grenier; Louis (Cambridge, MA), Plamondon; Louis (Cambridge, MA)
Assignee: LeukoSite, Inc. (Cambridge, MA)
Application Number:08/442,581
Patent Claims: 1. A compound of the structure: ##STR84## where P is, ##STR85## or ##STR86## where R.sup.7 is selected from the group consisting of ##STR87## or P is ##STR88## X.sup.2 is selected from the group consisting of ##STR89## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

where R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle or --Y--R.sup.6,

where Y is a chalcogen, and R.sup.6 is alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

2. A compound of claim 1, wherein P is N-morpholinylcarbonyl.

3. A compound of claim 1, wherein X.sup.2 is --C(O)NH--.

4. A compound of claim 1, wherein R.sup.2 and R.sup.3 are independently selected from the group consisting of alkyl and --CH.sub.2 R.sup.5, wherein R.sup.5 is as defined in claim 1.

5. A compound of claim 1, wherein R.sup.2 and R.sup.3 are independently selected from the group consisting of C.sub.1-4 alkyl or --CH.sub.2 R.sup.5, wherein R.sup.5 is selected from the group consisting of cycloalkyl, aryl or heterocycle.

6. A compound of claim 1, wherein R.sup.3 is isobutyl and R.sup.2 is --CH.sub.2 R.sup.5, wherein R.sup.5 is C.sub.5-10 aryl where one or more ring carbon atoms can be replaced by O, N or S.

7. A compound of claim 1, wherein R.sup.2 is: ##STR90##

8. A compound of claim 1, wherein Z.sup.1 and Z.sup.2 are both hydroxy.

9. A compound of claim 1, wherein Z.sup.1 and Z.sup.2 together form a moiety derived from a dihydroxy compound selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol and diethanolamine.

10. A compound of claim 1, wherein X.sup.2 is --C(O)--NH--;

R is hydrogen or alkyl;

R.sup.3 is isobutyl;

R.sup.2 is --CH.sub.2 R.sup.5, wherein R.sup.5 is C.sub.5-10 aryl where one or more ring carbon atoms can be replaced by O, N or S; and

Z.sup.1 and Z.sup.2 are both hydroxy, or together Z.sup.1 and Z.sup.2 form a moiety derived from a dihydroxy compound selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol and diethanolamine.

11. The compound of claim 1, wherein said compound is one of:

N-(2-pyridine)carbonyl-L-phenylalanine-L-leucine boronic acid,

N-(2-quinoline)carbonyl-L-phenylalanine-L-leucine boronic acid,

N-(3-furoyl)-L-phenylalanine-L-leucine boronic acid,

N-(2-pyrrolyl)carbonyl-L-phenylalanine-L-leucine boronic acid, or

N-(8-quinoline)sulfonyl-L-phenylalanine-L-leucine boronic acid.

12. A compound of claim 1 selected from the group consisting of:

N-(4-morpholine)carbonyl-.beta.-(1-naphthyl)-L-alanine-L-leucine boronic acid,

N-(8-quinoline)sulfonyl-.beta.-(1-naphthyl)L-alanine-L-leucine boronic acid,

N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid,

N-(2-quinoline)sulfonyl-L-homophenylalanine-L-leucine boronic acid,

N-(3-Pyridine)carbonyl-L-phenylalanine-L-leucine boronic acid, and

N-(4-Morpholine)carbonyl-L-phenylalanine-L-leucine boronic acid.

13. A compound of the structure: ##STR91## where P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR92## R is hydrogen or alkyl; R.sup.3 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

R.sup.2 is naphthylmethyl, pyridylmethyl, or quinolylmethyl,

R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle or --Y--R.sup.6,

where Y is a chalcogen, and R.sup.6 is alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

14. A compound of claim 13, wherein X.sup.2 is --C(O)NH--.

15. A compound of claim 13, wherein R.sup.3 is isobutyl.

16. A compound of claim 13, wherein Z.sup.1 and Z.sup.2 are both hydroxy.

17. A compound of claim 13, wherein Z.sup.1 and Z.sup.2 together form a dihydroxy moiety selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol and diethanolamine.

18. A compound of claim 13, wherein

X.sup.2 is --C(O)--NH--;

R is hydrogen or alkyl;

R.sup.3 is isobutyl; and

Z.sup.1 and Z.sup.2 are both hydroxy, or together Z.sup.1 and Z.sup.2 form a moiety derived from a dihydroxy compound selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol and diethanolamine.

19. A method for reducing the rate of muscle protein degradation in a cell comprising contacting said cell with a proteasome inhibitor of the structure: ##STR93## where P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR94## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5, heterocycle, or -chalcogen-alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

20. The method of claim 19 wherein P is ##STR95## and R.sup.7 is alkyl, aryl, alkaryl, aralkyl, or if P is ##STR96## or ##STR97## heterocycle.

21. The method of claim 19 wherein X.sup.2 is ##STR98##

22. The method of claim 19 wherein R.sup.2 selected from the group consisting of alkyl and --CH.sub.2 --R.sup.5, where R.sup.5 is aryl, alkaryl, cycloalkyl, or heterocycle.

23. The method of claim 19 wherein the proteasome inhibitor is selected from the group consisting of: N-(4-morpholine)carbonyl-.beta.-(1-naphthyl)-L-alanine-L-leucine boronic acid,

N-(8-quinoline)sulfonyl-.beta.-(1-naphthyl)L-alanine-L-leucine boronic acid,

N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid,

N-(2-quinoline)sulfonyl-L-homophenylalanine-L-leucine boronic acid,

N-(3-Pyridine)carbonyl-L-phenylalanine-L-leucine boronic acid, and

N-(4-Morpholine)carbonyl-L-phenylalanine-L-leucine boronic acid.

24. The method of claim 19, wherein P is ##STR99## and R.sup.7 is alkyl, aryl, aralkyl or heterocycle.

25. The method of claim 24, wherein R.sup.7 is ##STR100##

26. The method of claim 19, wherein R.sup.2, or R.sup.3 is arylalkyl of 6 to 14 carbon atoms, wherein 1 or more carbon is replaced by oxygen, nitrogen, or sulfur.

27. The method of claim 26, wherein R.sup.2, or R.sup.3 is

28. A method for reducing the rate of intracellular protein breakdown comprising contacting cells with a proteasome inhibitor of the structure: where

P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR101## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

where R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle, or -chalcogen-alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

29. A method for reducing the rate of degradation of p53 protein in a cell comprising administering to said cell a proteasome inhibitor of the structure: ##STR102## where P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR103## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

where R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle, or -chalcogen-alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

30. A method for inhibiting cyclin degradation in a cell comprising contacting said cell with a proteasome inhibitor of the structure: ##STR104## where P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR105## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

where R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle, or -chalcogen-alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

31. A method for inhibiting antigen presentation in a cell comprising administering to said cell a proteasome inhibitor of the structure: ##STR106## where P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR107## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

where R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle, or -chalcogen-alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

32. A method for inhibiting cell adhesion in an animal comprising administering to said animal a proteasome inhibitor of the structure: ##STR108## where P is H or an amino-group-protecting moiety;

X.sup.2 is selected from the group consisting of ##STR109## R is hydrogen or alkyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle and --CH.sub.2 --R.sup.5,

where R.sup.5 is aryl, aralkyl, alkaryl, cycloalkyl, heterocycle, or -chalcogen-alkyl;

Z.sup.1 and Z.sup.2 are independently alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and

A is 0.

33. A method for treating cancer in a patient, comprising administering to said patient a compound of claim 1.

34. A method for treating cancer in a patient, comprising administering to said patient a compound of claim 13.

35. A method for inhibiting HIV infection in an animal comprising administering to said animal a compound of claim 1.

36. A method for inhibiting HIV infection in an animal comprising administering to said animal a compound of claim 13.

37. A method for reducing the rate of degradation of p53 protein in a cell comprising administering to said cell a compound of claim 1.

38. A method for reducing the rate of degradation of p53 protein in a cell comprising administering to said cell a compound of claim 13.

39. A method for inhibiting cyclin degradation in a cell comprising contacting said cell with a compound of claim 1.

40. A method for inhibiting cyclin degradation in a cell comprising contacting said cell with a compound of claim 13.

41. A method for inhibiting NF-.kappa.B dependent cell adhesion in an animal comprising administering to said animal a compound of claim 1.

42. A method for inhibiting NF-.kappa.B dependent cell adhesion in an animal comprising administering to said animal a compound of claim 13.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.